Why the study?
Insulin resistance involves ectopic fat accumulation causing cardiac diastolic dysfunction and nonalcoholic fatty liver disease, but whether the PPARα agonist ciprofibrate directly impacts cardiac and hepatic metabolism and improves insulin sensitivity and cardiac function was unknown.
Does ciprofibrate improve insulin sensitivity and cardiac function in insulin-resistant male volunteers?
Does ciprofibrate improve insulin sensitivity and cardiac function in insulin-resistant male volunteers?
In insulin-resistant men, the PPARα agonist ciprofibrate did not improve whole-body insulin sensitivity or cardiac function, but instead increased hepatic lipid accumulation.
Answers are grounded in this paper and cite their sources.
No cardiac benefit from ciprofibrate in insulin resistance; leaves open PPARα effects on diastolic dysfunction.
Objective Insulin resistance is characterized by ectopic fat accumulation leading to cardiac diastolic dysfunction and nonalcoholic fatty liver disease. The objective of this study was to determine whether treatment with the peroxisome proliferator‐activated receptor‐α (PPARα) agonist ciprofibrate has direct effects on cardiac and hepatic metabolism and can improve insulin sensitivity and cardiac function in insulin‐resistant volunteers. Methods Ten insulin‐resistant male volunteers received 100 mg/d of ciprofibrate and placebo for 5 weeks in a randomized double‐blind crossover study. Insulin‐stimulated metabolic rate of glucose (MRgluc) was measured using dynamic 18 F‐fluorodeoxyglucose‐positron emission tomography ( 18 F‐FDG‐PET). Additionally, cardiac function, whole‐body insulin sensitivity, intrahepatic lipid content, skeletal muscle gene expression, 24‐hour blood pressure, and substrate metabolism were measured. Results Whole‐body insulin sensitivity, energy metabolism, and body composition were unchanged after ciprofibrate treatment. Ciprofibrate treatment decreased insulin‐stimulated hepatic MRgluc and increased hepatic lipid content. Myocardial net MRgluc tended to decrease after ciprofibrate treatment, but ciprofibrate treatment had no effect on cardiac function and cardiac energy status. In addition, no changes in PPAR‐related gene expression in muscle were found. Conclusions Ciprofibrate treatment increased hepatic lipid accumulation and lowered MRgluc, without affecting whole‐body insulin sensitivity. Furthermore, parameters of cardiac function or cardiac energy status were not altered upon ciprofibrate treatment.
No takes yet. Share an insight, caveat, or question.
Wit‐Verheggen et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: